FDA gives combo blood pressure tablet green light

The FDA approved a pill that combines a calcium channel blocker and an ACE inhibitor as a treatment for hypertension.

The approved tablets combine perindopril arginine and amlodipine under the brand name Prestalia (Symplmed Pharmaceuticals). The fixed-dose tablets are designed to reduce diastolic and systolic blood pressure in patients whose hypertension is not adequately treated by a single therapy. The combination pill also can be prescribed for patients whose physicians conclude likely will need several drugs to meet their blood pressure targets.

Cincinnati-based Symplmed Pharmaceuticals licenses Prestalia from the French company Servier. Symplmed plans to make the tablets available in the U.S. in the first quarter of 2015.

 

Candace Stuart, Contributor

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.